EX-16.1 2 tm2421756d1_ex16-1.htm EXHIBIT 16.1

Exhibit 16.1

 

August 15, 2024

 

U.S. Securities and Exchange Commission
100 F Street, NE

Washington, DC 20549

 

Ladies and Gentlemen:

 

We have read Item 4.01 of Form 8-K dated August 15, 2024 of Entero Therapeutics, Inc. and are in agreement with the statements therein concerning Forvis Mazars, LLP. We have no basis to agree or disagree with other statements of the registrant contained therein.

 

/s/ Forvis Mazars, LLP

 

New York, New York